Weekly Cosmetic Research Analysis
This week’s cosmetic-related research emphasized mechanistic, randomized, and procedural evidence that can change practice: a multicenter RCT plus multi-omics identified tretinoin (ATRA) as a metabolically acting topical that prevents hypertrophic scars via the RARα–HIC1–PCK1/2 axis; a NEJM randomized trial showed no benefit of higher-dose ivermectin over standard dosing when combined with permethrin for severe scabies, clarifying dosing standards; and a systematic review found high-frequency ul
Summary
This week’s cosmetic-related research emphasized mechanistic, randomized, and procedural evidence that can change practice: a multicenter RCT plus multi-omics identified tretinoin (ATRA) as a metabolically acting topical that prevents hypertrophic scars via the RARα–HIC1–PCK1/2 axis; a NEJM randomized trial showed no benefit of higher-dose ivermectin over standard dosing when combined with permethrin for severe scabies, clarifying dosing standards; and a systematic review found high-frequency ultrasound improves safety monitoring and objective volumetric outcomes in facial autologous fat grafting. Additional notable work covered exosome-mediated hair regeneration, nanoparticle safety mechanisms, and device/material innovations for cosmetic formulations and colorants.
Selected Articles
1. From RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation.
A multicenter, double-blind RCT showed topical tretinoin is non-inferior to silicone gel for preventing hypertrophic scars, and integrated multi-omics plus in vivo and genetic models identified that ATRA activates RARα to upregulate HIC1 and PCK1/2, shifting fibroblast metabolism from aerobic glycolysis toward gluconeogenesis and reducing myofibroblast activation and scar formation.
Impact: Bridges high-level clinical evidence with mechanistic validation to identify a druggable metabolic axis (RARα–HIC1–PCK1/2) for scar prevention, elevating tretinoin from empirical use to mechanism-based therapy.
Clinical Implications: Consider topical tretinoin as an evidence-based option for hypertrophic scar prevention; clinicians should monitor dosing/tolerability and await further large-scale RCTs and dosing optimization across skin types. The identified metabolic pathway suggests potential adjunctive pharmacologic strategies targeting RARα/HIC1/PCK enzymes.
Key Findings
- Tretinoin demonstrated non-inferiority to silicone gel for hypertrophic scar prevention in a multicenter double-blind RCT.
- Mechanistically, ATRA activates RARα to upregulate HIC1 and PCK1/2, suppressing aerobic glycolysis and promoting gluconeogenesis in hypertrophic-scar fibroblasts, reducing myofibroblast activation.
2. Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.
A blinded randomized trial of 132 adults with severe scabies compared higher-dose (400 μg/kg) versus standard-dose (200 μg/kg) oral ivermectin, both combined with 5% permethrin. The higher dose was not superior (cure rates 75% vs 82%), and no safety concerns were identified, supporting continued use of standard dosing within combination regimens.
Impact: A high-quality negative RCT in a major clinical journal clarifies dosing standards for a common dermatologic/parasitic condition, informing guideline developers and clinicians to avoid unnecessary dose escalation.
Clinical Implications: Continue standard-dose ivermectin (200 μg/kg schedule used in trial) with 5% permethrin for severe scabies rather than escalating ivermectin dose; focus on adherence and combination therapy protocols, and extend investigations to pediatrics and immunocompromised patients.
Key Findings
- No superiority of higher-dose ivermectin (400 μg/kg) over standard-dose (200 μg/kg) when combined with 5% permethrin (cure rates 75% vs 82%).
- Blinded randomized design with parasitologic and dermoscopic confirmation and no safety signal identified.
3. Ultrasound-Assisted Facial Autologous Fat Grafting: A Systematic Review of Perioperative Safety and Volumetric Outcomes.
A PRISMA-compliant systematic review (12 studies, 885 patients) found that high-frequency ultrasound supports vascular mapping, filler identification, intraoperative confirmation of cannula location, and objective volumetric retention tracking in facial autologous fat grafting. Comparative data suggested increased injection volumes and higher patient satisfaction without increased complications; standardized protocols and higher-quality trials are still needed.
Impact: Aggregates growing evidence that point-of-care ultrasound can materially improve safety stratification and objective outcome measurement in facial fat grafting—a field with rare but severe vascular complications and variable retention.
Clinical Implications: Clinicians performing facial fat grafting should consider adopting standardized high-frequency ultrasound protocols for pre/intra/postoperative mapping and volumetric monitoring, paired with operator training to reduce risk and guide staged grafting.
Key Findings
- HFUS aided vascular mapping, filler characterization, real-time safe-plane confirmation, and postoperative retention tracking across 12 studies (885 patients).
- Comparative data in one cohort showed higher injection volumes and greater satisfaction (92% vs 74%) with ultrasound guidance without increased complications; retention stabilized at ~50–70% by 1 year.